Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

DSpace/Manakin Repository

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

Show simple item record

dc.contributor.author Mendizabal, Manuel.
dc.contributor.author Haddad, Leila.
dc.contributor.author Gallardo, Patricia.
dc.contributor.author Ferrada, Alejandro.
dc.contributor.author Soza, Alejandro.
dc.contributor.author Adrover, Raul.
dc.contributor.author Aravena, Edmundo.
dc.contributor.author et al.
dc.date.accessioned 2020-03-02T18:29:55Z
dc.date.available 2020-03-02T18:29:55Z
dc.date.issued 2017-09-01
dc.identifier.citation J Med Virol. 2017 Sep;89(9):1590-1596. en_US
dc.identifier.issn 0146-6615
dc.identifier.uri https://riu.austral.edu.ar/handle/123456789/836
dc.description.abstract Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region. en_US
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.subject Antiviral agents en_US
dc.subject Disease control en_US
dc.subject Hepatitis C virus en_US
dc.subject Public policy en_US
dc.title Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. en_US
dc.type Article en_US


Files in this item

Files Size Format View Description
J Med Virol. 2017 Sep;89(9);1590-1596.pdf 127.0Kb PDF View/Open IA - Mendizabal

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account